STOCK TITAN
  1. Home
  2. CNAT

CNAT Stock Price, News & Analysis

CNAT NASDAQ

Company Description

CNAT (NASDAQ: CNAT) is a publicly traded biotechnology company in the Health Technology sector.

CNAT stock has declined 33.4% over the past year.

This page provides a comprehensive overview of CNAT stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-33.42%
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding

CNAT (CNAT) stock. Over the past 12 months, the stock has lost 33.4%.

Latest News

View All
+29.34%

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

clinical trial
+7.50%

Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

clinical trial fda approval
-12.55%

The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020

acquisition
+0.97%

Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update

earnings

CNAT has 4 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 1 with negative movement. Key topics include clinical trial, fda approval, acquisition, earnings. View all CNAT news →

SEC Filings

View All

No SEC filings available for CNAT.

Financial Highlights

View Full Financials
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

CNAT Company Profile & Sector Positioning

CNAT (CNAT) operates in the Biotechnology industry within the broader Health Technology sector and is listed on the NASDAQ.